Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Protagonist Therapeutics, Inc.
  6. News
  7. Summary
    PTGX   US74366E1029

PROTAGONIST THERAPEUTICS, INC.

(PTGX)
  Report
Real-time Estimate Cboe BZX  -  12:59:21 2023-01-30 pm EST
12.84 USD   -4.86%
01/11Transcript : Protagonist Therapeutics, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-11-2023 07:30 AM
CI
01/06Protagonist Therapeutics, Inc : Change in Directors or Principal Officers (form 8-K)
AQ
01/06Protagonist Therapeutics, Inc. Announces David Liu, Chief R&D Strategy Officer, Transitioned to Part-Time R&D Strategy Advisor
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

HC Wainwright Lowers Price Target on Protagonist Therapeutics to $33 From $50, Maintains Buy Rating

11/10/2022 | 09:41am EST
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about PROTAGONIST THERAPEUTICS, INC.
01/11Transcript : Protagonist Therapeutics, Inc. Presents at 41st Annual J.P. Morg..
CI
01/06Protagonist Therapeutics, Inc : Change in Directors or Principal Officers (form 8-K)
AQ
01/06Protagonist Therapeutics, Inc. Announces David Liu, Chief R&D Strategy Officer, Transit..
CI
2022Protagonist Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conferenc..
PR
2022Protagonist Therapeutics to Participate in the JMP Securities Hematology and Oncology S..
PR
2022Protagonist Therapeutics Reports Granting of Inducement Award
PR
2022HC Wainwright Lowers Price Target on Protagonist Therapeutics to $33 From $50, Maintain..
MT
2022PROTAGONIST THERAPEUTICS, INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
AQ
2022Protagonist Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine ..
CI
2022Protagonist Therapeutics : Q3 Earnings Snapshot
AQ
More news
Analyst Recommendations on PROTAGONIST THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 31,5 M - -
Net income 2022 -127 M - -
Net cash 2022 49,0 M - -
P/E ratio 2022 -5,27x
Yield 2022 -
Capitalization 664 M 664 M -
EV / Sales 2022 19,5x
EV / Sales 2023 52,0x
Nbr of Employees 122
Free-Float 98,5%
Chart PROTAGONIST THERAPEUTICS, INC.
Duration : Period :
Protagonist Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROTAGONIST THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 13,49 $
Average target price 33,50 $
Spread / Average Target 148%
EPS Revisions
Managers and Directors
Dinesh V. Patel President, Chief Executive Officer & Director
Asif Ali Chief Financial Officer & Executive Vice President
Harold E. Selick Chairman
Mark L. Smythe Vice President-Technology
Samuel R. Saks Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PROTAGONIST THERAPEUTICS, INC.23.65%664
MODERNA, INC.5.42%72 745
LONZA GROUP AG17.24%42 787
IQVIA HOLDINGS INC.12.00%42 622
ALNYLAM PHARMACEUTICALS, INC.-2.64%28 465
SEAGEN INC.9.46%26 117